Comparable stake leader
FMR LLC
SEC ownership of Moderna, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001682852.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
05 Aug 2026
- Public ticker
- MRNA on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
05 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001682852
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Moderna, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
05 Aug 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
13%
VANGUARD CAPITAL MANAGEMENT LLC
6.5%
Capital World Investors
5.6%
BAILLIE GIFFORD & CO
4.6%
Stephane Bancel
3.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
13%
from 13D/G
|
$3,631,748,191
51,859,891 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Capital Management
|
6.5%
from 13D/G
|
$1,625,311,704
23,208,792 shares
|
— | 30 Jun 2026 |
| Capital World Investors |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$1,560,053,964
22,276,996 shares
|
— | 30 Jun 2026 |
| BAILLIE GIFFORD & CO |
13D/G
13F
Company
|
4.6%
|
$1,275,020,663
18,206,778 shares
|
-$166,232,732 | 30 Jun 2026 |
| Stephane Bancel |
3/4/5
Chief Executive Officer, Director
|
3.3%
|
$910,749,953
13,005,140 shares
|
-$28,715,011 | 05 Aug 2026 |
| BlackRock, Inc. |
13F
Company
|
7.7%
|
$2,142,876,625
30,599,409 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
4%
|
$1,101,305,296
15,726,193 shares
|
— | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
3.9%
|
$1,091,159,349
15,581,313 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$64,634,621.
Buys
$0
Insiders: 0
Sells
$64,634,621
Insiders: 6
Net
-$64,634,621
Shares: -994,803
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 994,803
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 671,464 | $0 | $49,182,805 | -$49,182,805 |
| 3-6 | 0 | 125,088 | $0 | $6,193,713 | -$6,193,713 |
| 6-9 | 0 | 173,894 | $0 | $8,540,886 | -$8,540,886 |
| 9-12 | 0 | 24,357 | $0 | $717,216 | -$717,216 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to Moderna, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
Stephane Bancel
Net 12M change
-$64,634,621
Latest report
14 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stephane Bancel | Chief Executive Officer, Director | $910,749,953 | -$28,715,011 | -3.1% | Median | 05 Aug 2026 |
| Ph.D. Noubar B. Afeyan | Director | $348,393,290 | -$1,137,185 | -0.33% | Mixed | 21 May 2026 |
| Stephen Hoge | President | $243,711,297 | -$28,433,106 | -10% | Mixed | 14 Sep 2026 |
| Paul Sagan | Director | $15,693,665 | Mixed | 30 Apr 2025 | ||
| James M. Mock | Chief Financial Officer | $8,284,336 | -$4,685,094 | -36% | Mixed | 10 Sep 2026 |
| Shannon Thyme Klinger | Chief Legal Officer | $5,732,153 | -$1,385,363 | -19% | Mixed | 04 Sep 2026 |
| Stephen Berenson | Director | $2,517,789 | Mixed | 03 May 2024 | ||
| Francois Nader | Director | $1,665,274 | Mixed | 06 May 2026 | ||
| Arpa Garay | Chief Commercial Officer | $1,524,005 | Mixed | 05 Dec 2023 | ||
| Juan Andres | Chief Technical Operations and Quality Officer | $1,330,232 | Mixed | 28 Dec 2022 | ||
| Elizabeth G. Nabel | Director | $1,092,320 | Mixed | 06 May 2026 | ||
| Sandra Horning | Director | $1,055,135 | Mixed | 06 May 2026 | ||
| David W. Meline | Chief Financial Officer | $645,077 | Mixed | 09 Aug 2022 | ||
| Abbas Hussain | Director | $628,264 | -$278,862 | -31% | Mixed | 06 May 2026 |
| David M. Rubenstein | Director | $572,203 | Mixed | 06 May 2026 | ||
| Paul Burton | Chief Medical Officer | $541,865 | Mixed | 04 Nov 2022 | ||
| Elizabeth E. Tallett | Director | $241,858 | Mixed | 06 May 2026 | ||
| Lori M. Henderson | General Counsel and Secretary | $93,614 | Mixed | 27 May 2021 | ||
| Robert Langer | Director | Mixed | 06 May 2024 | |||
| Soria Ester Banque | Chief Commercial Officer | Mixed | 05 Jul 2026 |
Recent insider transactions for Moderna, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Stephen Hoge | MRNA | Common Stock | Sale | -2.51% | $5,883,846 | $146.07 | -40,281 | 1,562,029 | 15 Sep 2026 | Direct |
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 5.01% | 76,452 | 1,602,310 | 15 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Stock Option (Right to Buy) | Options Exercise | -20% | -76,452 | 305,810 | 15 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Sale | -2.57% | $5,807,574 | $144.13 | -40,294 | 1,525,858 | 14 Sep 2026 | Direct |
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 5.13% | 76,453 | 1,566,152 | 14 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Stock Option (Right to Buy) | Options Exercise | -16.7% | -76,453 | 382,262 | 14 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Sale | -37% | $4,685,094 | $134.49 | -34,836 | 59,375 | 10 Sep 2026 | Direct |
| James M. Mock | MRNA | Common Stock | Options Exercise | 26.7% | 19,836 | 94,211 | 10 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Stock Option (Right to Buy) | Options Exercise | -31.2% | -19,836 | 43,642 | 10 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -7.12% | -5,704 | 74,375 | 04 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 17.3% | 11,797 | 80,079 | 04 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -10% | -11,797 | 106,179 | 04 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -6.55% | -5,704 | 81,340 | 04 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 15.7% | 11,797 | 87,044 | 04 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -10% | -11,797 | 106,179 | 04 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -1.37% | -1,048 | 75,247 | 01 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Sale | -4.47% | $485,766 | $139.95 | -3,471 | 74,129 | 01 Sep 2026 | Direct |
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 7.83% | 5,637 | 77,600 | 01 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -9.09% | -2,166 | 21,661 | 01 Sep 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Stock Option (Right to Buy) | Options Exercise | -9.09% | -3,471 | 34,716 | 01 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -1.72% | -1,197 | 68,282 | 01 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 3.69% | 2,475 | 69,479 | 01 Sep 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -9.09% | -2,475 | 24,755 | 01 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.3% | -4,489 | 1,489,699 | 01 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 0.63% | 9,283 | 1,494,188 | 01 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -9.09% | -9,283 | 92,828 | 01 Sep 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.02% | -296 | 1,484,905 | 28 Aug 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 0.04% | 611 | 1,485,201 | 28 Aug 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -33.4% | -611 | 1,221 | 28 Aug 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -0.22% | -160 | 74,129 | 28 Aug 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 0.44% | 329 | 74,289 | 28 Aug 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -33.3% | -329 | 658 | 28 Aug 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -0.24% | -160 | 67,004 | 28 Aug 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 0.49% | 329 | 67,164 | 28 Aug 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -33.3% | -329 | 658 | 28 Aug 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Tax liability | -0.05% | -695 | 1,484,590 | 27 Aug 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Options Exercise | 0.1% | 1,437 | 1,485,285 | 27 Aug 2026 | Direct | ||
| Stephen Hoge | MRNA | Restricted Stock Units | Options Exercise | -14.3% | -1,437 | 8,621 | 27 Aug 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Tax liability | -0.5% | -375 | 73,960 | 27 Aug 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Common Stock | Options Exercise | 1.05% | 774 | 74,335 | 27 Aug 2026 | Direct | ||
| Shannon Thyme Klinger | MRNA | Restricted Stock Units | Options Exercise | -14.3% | -774 | 4,642 | 27 Aug 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Tax liability | -0.56% | -375 | 66,835 | 27 Aug 2026 | Direct | ||
| James M. Mock | MRNA | Common Stock | Options Exercise | 1.17% | 774 | 67,210 | 27 Aug 2026 | Direct | ||
| James M. Mock | MRNA | Restricted Stock Units | Options Exercise | -14.3% | -774 | 4,642 | 27 Aug 2026 | Direct | ||
| Stephane Bancel | MRNA | Common Stock | Options Exercise | 4.08% | 252,469 | 6,440,260 | 06 Aug 2026 | Direct | ||
| Stephane Bancel | MRNA | Stock Option (Right to Buy) | Options Exercise | -100% | -252,469 | 0 | 06 Aug 2026 | Direct | ||
| Stephane Bancel | MRNA | Common Stock | Sale | -7.47% | $28,715,011 | $57.52 | -499,246 | 6,187,791 | 05 Aug 2026 | Direct |
| Stephane Bancel | MRNA | Common Stock | Options Exercise | 8.07% | 499,246 | 6,687,037 | 05 Aug 2026 | Direct | ||
| Stephane Bancel | MRNA | Stock Option (Right to Buy) | Options Exercise | -88.5% | -499,246 | 64,928 | 05 Aug 2026 | Direct | ||
| Stephen Hoge | MRNA | Common Stock | Sale | -3.47% | $3,605,514 | $67.60 | -53,336 | 1,483,848 | 15 Jul 2026 | Direct |
* marks a reported price that did not pass the local price check.